Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $340,039.48 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 22,564 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $15.07, for a total value of $340,039.48. Following the sale, the insider directly owned 271,154 shares in the company, valued at $4,086,290.78. The trade was a 7.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.08, for a total value of $430,749.44.
• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.09, for a total value of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $12.79 on Monday. The company has a market capitalization of $1.97 billion, a PE ratio of -31.97 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 12 month low of $6.77 and a 12 month high of $20.76. The stock’s fifty day simple moving average is $14.95 and its 200 day simple moving average is $15.99.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue was up 51.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.23) EPS. Analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ADPT. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently added to or reduced their stakes in ADPT. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the 4th quarter worth about $65,942,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after acquiring an additional 2,062,282 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.